Roivant Sciences(ROIV) - 2026 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported a non-GAAP net loss of $167 million for the quarter, with R&D expenses at $165 million and G&A expenses at $175 million [27][28] - The company maintains a strong cash position with $4.5 billion in consolidated cash, providing ample capital to reach profitability [28] Business Line Data and Key Metrics Changes - The NDA for brepocitinib in dermatomyositis has been submitted, and the phase 2b study for 1402 in D2T-RA has fully enrolled [5][6] - The phase 2 study for mosliciguat in PH-ILD has also fully enrolled, with top-line data expected in the second half of the year [6][25] Market Data and Key Metrics Changes - The company is targeting a large addressable patient population for brepocitinib, particularly in orphan inflammatory diseases with high unmet needs [23][34] - The market opportunity for cutaneous sarcoidosis is estimated at around 40,000 eligible patients, which is slightly smaller than the dermatomyositis opportunity [75] Company Strategy and Development Direction - The company is focused on expanding the development of brepocitinib into additional indications, including other forms of sarcoidosis [33][94] - The company aims to leverage its unique TYK2 and JAK1 inhibition mechanism to explore new therapeutic areas with high unmet needs [93] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the strong phase 2 data for brepocitinib, indicating it could be a significant treatment option for patients with cutaneous sarcoidosis [9][23] - The company anticipates a busy year ahead with multiple pivotal study readouts and potential commercial launches [30][31] Other Important Information - The jury trial against Moderna is scheduled for March 9, with recent favorable decisions regarding summary judgment [26][27] - The company is preparing for pivotal data readouts in 2027 for its FcRn product, IMVT-1402, which is expected to have best-in-class efficacy [24] Q&A Session Summary Question: What are the further development opportunities for brepocitinib? - Management is enthusiastic about further development and sees brepocitinib as a strong agent for patient populations in need, with ongoing considerations for other forms of sarcoidosis [33] Question: Can you provide more details on the baseline characteristics of the CSAMI numbers? - Management noted that there were significant differences in baseline characteristics, including disease duration and morphology, which may have influenced the results [42] Question: What are the pricing considerations for brepocitinib? - Pricing has not been finalized, but management indicated it would be positioned as an orphan-priced drug, with considerations based on existing therapies [48] Question: What is the expected size and design of the phase 3 study? - Management indicated that the phase 3 study would likely be similar in size to the dermatomyositis trial, but final details will depend on discussions with the FDA [56][75] Question: What percentage of patients in the Beacon study had organ involvement? - Approximately 60% of patients had pulmonary involvement, and exploratory endpoints related to organ involvement were collected but not analyzed yet [82]